The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination

2021 ◽  
pp. 172460082110494
Author(s):  
Zhimao Chen ◽  
Xiangzheng Liu ◽  
Xueqian Shang ◽  
Kang Qi ◽  
Shijie Zhang
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Tumor Markers ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Neuron Specific Enolase ◽  
Small Cell ◽  
Small Cell Lung

Background The diagnostic value of six tumor markers was investigated and the appropriate combinations of those tumor markers to discriminate small cell lung cancer was explored. Methods Patients suspected with lung cancer (1938) were retrospectively analyzed. Candidate tumor markers from carcinoembryonic antigen (CEA), squamous cell carcinoma-related antigen (SCC), cytokeratin 19 fragment 21-1 (CYFRA 21-1), neuron-specific enolase (NSE), tissue polypeptide antigen (TPA), and progastrin releasing peptide (ProGRP) were selected to construct a logistic regression model. The receiver operating characteristic curve was used for evaluating the diagnostic value of the tumor markers and the predictive model. Results ProGRP had the highest positive rate (72.3%) in diagnosed small cell lung cancer, followed by neuron-specific enolase (68.3%), CYFRA21-1 (50.5%), carcinoembryonic antigen (45.5%), tissue polypeptide antigen (30.7%), and squamous cell carcinoma-related antigen (5.9%). The predictive model for small cell lung cancer discrimination was established, which yielded the highest area under the curve (0.888; 95% confidence interval: 0.846–0.929), with a sensitivity of 71.3%, a specificity of 95.0%, a positive predictive value of 49.0%, and a negative predictive value of 98.0%. Conclusions Combining tumor markers can improve the efficacy for small cell lung cancer discrimination. A predictive model has been established in small cell lung cancer differential diagnosis with preferable efficacy.

scholarly journals Diagnostic and Prognostic Significance of Serum Tumor Markers in Patients with Lung Cancer

2021 ◽  
Author(s):  
Suipeng Chen ◽  
Mengjiao Kuang ◽  
Shishi Wang ◽  
Shirui Huang ◽  
Jizhen Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Tumor Markers ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Abstract Background: Tumor markers CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag were routinely used for lung cancer. The objective of this study was to evaluate the diagnostic and prognostic value of these markers.Methods: The levels of 5 serum tumor markers were measured in 255 patients with lung cancer (44 squamous cell carcinoma, 183 adenocarcinoma, 28 small cell lung cancer), 103 patients with benign lung disease, and 120 healthy controls. The relevant clinical data of the patients were collected to analyze the expression of CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag in the serum of lung cancer and their correlation with prognosis.Results: The positive rates and expression levels of CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag in the lung cancer group were higher than those in patients with benign lung diseases and healthy controls. CYFRA21-1 and SCC-Ag were highly expressed in lung squamous cell carcinoma, and NSE and proGRP were highly expressed in small cell lung cancer. The expression levels of CYFRA 21-1, NSE, and proGRP in small cell lung cancer were higher than those in non-small cell lung cancer. The levels of CEA, CYFARA21-1, NSE, and proGRP were linearly correlated with the occurrence of lung cancer, while the level of SCC-Ag was not significantly correlated with the occurrence of lung cancer. What’s more, the levels of CYFAR21-1 and NSE in the death group of lung cancer patients were higher than those in the survival group.Conclusion: CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag played a good role in diagnosing lung cancer. CYFRA21-1 and SCC-Ag can be used as markers for the diagnosis of squamous cell carcinoma, and NSE and proGRP can be used as markers for small cell lung cancer. Meanwhile, the combined detection of CEA, CYFARA21-1, NSE, and proGRP had the highest diagnostic accuracy for lung cancer. Furthermore, CYFAR21-1 and NSE can be used to evaluate the prognosis of lung cancer patients.

scholarly journals Diagnostic and Prognostic Significance of Serum Tumor Markers in Patients With Lung Cancer

2022 ◽  
Author(s):  
Suipeng Chen ◽  
Mengjiao Kuang ◽  
ShiShi Wang ◽  
Shirui Huang ◽  
Jizhen Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Tumor Markers ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Abstract Background: Tumor markers CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag were routinely used for lung cancer. The objective of this study was to evaluate the diagnostic and prognostic value of these markers.Methods: The levels of 5 serum tumor markers were measured in 255 patients with lung cancer (44 squamous cell carcinoma, 183 adenocarcinoma, 28 small cell lung cancer), 103 patients with benign lung disease, and 120 healthy controls. The relevant clinical data of the patients were collected to analyze the expression of CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag in the serum of lung cancer and their correlation with prognosis.Results: The positive rates and expression levels of CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag in the lung cancer group were higher than those in patients with benign lung diseases and healthy controls. CYFRA21-1 and SCC-Ag were highly expressed in lung squamous cell carcinoma, and NSE and proGRP were highly expressed in small cell lung cancer. The expression levels of CYFRA 21-1, NSE, and proGRP in small cell lung cancer were higher than those in non-small cell lung cancer. The levels of CEA, CYFARA21-1, NSE, and proGRP were linearly correlated with the occurrence of lung cancer, while the level of SCC-Ag was not significantly correlated with the occurrence of lung cancer. What’s more, the levels of CYFAR21-1 and NSE in the death group of lung cancer patients were higher than those in the survival group.Conclusion: CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag played a good role in diagnosing lung cancer. CYFRA21-1 and SCC-Ag can be used as markers for the diagnosis of squamous cell carcinoma, and NSE and proGRP can be used as markers for small cell lung cancer. Meanwhile, the combined detection of CEA, CYFARA21-1, NSE, and proGRP had the highest diagnostic accuracy for lung cancer. Furthermore, CYFAR21-1 and NSE can be used to evaluate the prognosis of lung cancer patients.

A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer

2007 ◽  
Vol 25 (2) ◽  
pp. 187-189 ◽  
Author(s):  
Katsunori Kagohashi ◽  
Hiroaki Satoh ◽  
Hiroichi Ishikawa ◽  
Morio Ohtsuka ◽  
Kiyohisa Sekizawa
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Serum Marker ◽  
Small Cell ◽  
Squamous Cell Carcinoma Antigen ◽  
Small Cell Lung

scholarly journals Epidemiologic trends in lung cancer over two decades in Northern Greece: an analysis of bronchoscopic data

2016 ◽  
Vol 71 (4) ◽  
Author(s):  
T. Kontakiotis ◽  
N. Manolakoglou ◽  
F. Zoglopitis ◽  
D. Iakovidis ◽  
L. Sacas ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Northern Greece ◽  
Female Ratio

Background and Aim. The relative frequency of histological subtypes of lung cancer in Europe has changed dramatically during the 20th century. The aim of this study was to explore the changing epidemiology of lung cancer in Northern Greece over the last two decades. Methods. From the extensive database of the Bronchoscopy Unit of the G. Papanicolaou General Hospital, Thessaloniki, Greece, we identified all patients with a histologic and/or cytologic report positive for lung cancer over two consecutive decades. Results. Between 1/1/1986 and 31/12/2005 we identified 9981 patients with specimens positive for lung cancer. A significant increase in mean patient age was observed during the second decade (64.8±9.4 vs. 62.1±8.9, p=0.001). Men developed lung cancer ten times more often than women. The predominant histological type was squamous cell cancer in males (4203 cases, 45.7%) and adenocarcinoma (418 cases, 52.6%) in females. The number of lung cancer cases was significantly higher during the second decade compared to the first decade (5766 cases [57.8%] vs. 4215 cases [42.2%], respectively, p<0.001). There was a significant decrease in the percentage of squamous cell carcinoma in males in the second decade (2317 cases [44.1%] vs. 1886 cases [48.0%], p<0.001), and an increase in adenocarcinoma (1021 cases [19.4%] vs. 609 [11.6%], p<0.001). In females, the relative incidence of adenocarcinoma was decreased and that of squamous cell carcinoma was increased, but not significantly. There was no obvious change in the incidence of small cell lung cancer. Neoplastic lesions were most often located in the upper lobes. Conclusion. The number of lung cancer cases has increased in the last decade. Squamous lung cancer appears to be decreasing in men and increasing in women. Adenocarcinoma appears to be increasing in men and decreasing in women. There appears to be no change in small cell lung cancer. During the second decade there has been a significant decrease in the male: female ratio.

scholarly journals Mutation profile of non-small cell lung cancer revealed by next generation sequencing

2020 ◽  
Author(s):  
Ya-Sian Chang ◽  
Siang-Jyun Tu ◽  
Yu-Chia Chen ◽  
Ting-Yuan Liu ◽  
Ya-Ting Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Targeted Therapies ◽  
Small Cell ◽  
Small Cell Lung ◽  
Whole Exome

Abstract Background: Precision therapy for lung cancer requires comprehensive genomic analyses. Specific effects of targeted therapies have been reported in Asia populations, including Taiwanese, but genomic studies have rarely been performed in these populations. Method: We enrolled 72 patients with non-small cell lung cancer, of whom 61 had adenocarcinoma, 10 had squamous cell carcinoma, and 1 had combined adenocarcinoma and squamous cell carcinoma. Whole-exome or targeted gene sequencing was performed. To identify trunk mutations, we performed whole-exome sequencing in two tumor regions in four patients. Results: Nineteen known driver mutations in EGFR, PIK3CA, KRAS, CTNNB1, and MET were identified in 34 of the 72 tumors evaluated (47.22%). A comparison with the Cancer Genome Atlas dataset showed that EGFR was mutated at a much higher frequency in our cohort than in Caucasians, whereas KRAS and TP53 mutations were found in only 5.56% and 25% of our Taiwanese patients, respectively. We also identified new mutations in ARID1A, ARID2, CDK12, CHEK2, GNAS, H3F3A, KDM6A, KMT2C, NOTCH1, RB1, RBM10, RUNX1, SETD2, SF3B1, SMARCA4, THRAP3, TP53, and ZMYM2. Moreover, all ClinVar pathogenic variants were trunk mutations present in two regions of a tumor. RNA sequencing revealed that the trunk or branch genes were expressed at similar levels among different tumor regions.Conclusions: We identified novel variants potentially associated with lung cancer tumorigenesis. The specific mutation pattern in Taiwanese patients with non-small cell lung cancer may influence targeted therapies.

Claudin-1 Protein Expression Is a Good Prognostic Factor in Non-Small Cell Lung Cancer, but only in Squamous Cell Carcinoma Cases

2016 ◽  
Vol 23 (1) ◽  
pp. 151-156 ◽  
Author(s):  
Judit Moldvay ◽  
Katalin Fábián ◽  
Márta Jäckel ◽  
Zsuzsanna Németh ◽  
Krisztina Bogos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Prognostic Factor ◽  
Protein Expression ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document